1. Home
  2. REED vs PHIO Comparison

REED vs PHIO Comparison

Compare REED & PHIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Reed's Inc.

REED

Reed's Inc.

SELL

Current Price

$1.70

Market Cap

8.8M

Sector

N/A

ML Signal

SELL

Logo Phio Pharmaceuticals Corp.

PHIO

Phio Pharmaceuticals Corp.

HOLD

Current Price

$0.65

Market Cap

10.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
REED
PHIO
Founded
1987
2003
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
8.8M
10.1M
IPO Year
2009
2011

Fundamental Metrics

Financial Performance
Metric
REED
PHIO
Price
$1.70
$0.65
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
★ 231.9K
53.7K
Earning Date
11-10-2026
11-05-2026
Dividend Yield
N/A
N/A
EPS Growth
★ N/A
N/A
EPS
N/A
★ N/A
Revenue
★ $34,065,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$28.08
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
★ N/A
N/A
52 Week Low
$0.33
$0.70
52 Week High
$5.97
$1.88

Technical Indicators

Market Signals
Indicator
REED
PHIO
Relative Strength Index (RSI) 59.41 27.10
Support Level $1.52 N/A
Resistance Level $2.11 $1.12
Average True Range (ATR) 0.36 0.07
MACD 0.02 -0.01
Stochastic Oscillator 53.93 5.14

Price Performance

Historical Comparison
REED
PHIO

About REED Reed's Inc.

Reed's Inc is a branded beverage company offering a portfolio of natural, premium, and functional beverages under the Reed's and Virgil's brands. The company's portfolio of handcrafted, all-natural beverages is sold in outlets nationwide, including the natural and specialty food channel, grocery stores, mass merchants, drug stores, convenience stores, club stores, and on-premise locations, including bars and restaurants. The company operates in a single reportable segment, which consists of manufacturing carbonated beverages under Reed's and Virgil's brand names.

About PHIO Phio Pharmaceuticals Corp.

Phio Pharmaceuticals Corp is a clinical-stage biopharmaceutical company whose proprietary INTASYL small-interfering RNA gene silencing technology is designed to make immune cells more effective in killing tumor cells. Its pipeline programs are PH-762 and PH-894. The group is developing therapeutics that are designed to leverage INTASYL to precisely target specific proteins that reduce the body's ability to fight cancer, without the need for specialized formulations or drug delivery systems. It is committed to discovering and developing cancer treatments for patients by creating new pathways toward a cancer-free future. The Company operates with a single operating segment, the Clinical segment, and all assets are located in the United States.

Share on Social Networks: